QuantHealth Raises $45M to Predict Clinical Outcomes

The big picture: QuantHealth has raised $45 million in Series B funding to scale an ambitious idea: use AI to test clinical trials before drugmakers test them on patients. The round was led by Qumra Capital, with participation from Pitango HealthTech, Sanofi Ventures, Artofin Venture Capital Fund L.P., Bertelsmann Healthcare Investments (BHI), GC Ventures, NewHealth Ventures, Shoni Top Ventures, and Esplanade Ventures. This funding aims to address the high failure rate and significant costs associated with traditional drug development.

Why it matters:

• High Failure Rates: Over 90% of drugs entering clinical development eventually fail, with roughly 75% of those failures tied to efficacy and safety, incurring massive costs and delays.
• Early Decision-Making: QuantHealth’s AI simulations allow drugmakers to test trial designs and clinical decisions computationally, identifying flaws or promising alternatives before patient enrollment.
• Industry Adoption: The company already works with 12 of the top 20 pharmaceutical companies, demonstrating early market validation for its simulation-first approach.

How it works:

• Predictive Simulations: QuantHealth creates AI-powered simulations that combine trial models with large real-world datasets to predict outcomes based on patient populations, endpoints, and dosing.
• Pre-Trial Optimization: Researchers can evaluate various trial parameters to optimize study design, select better patient populations, or abandon unlikely programs earlier.
• Expanded Coverage: The platform has simulated over 600 trials across 30 indications, with plans to extend coverage beyond 40, focusing on oncology, cardiometabolic, and inflammation.

The catch: While AI simulations offer significant potential to de-risk clinical development, they cannot replace human clinical trials, which remain the gold standard for establishing drug safety and efficacy. Pharmaceutical companies will require extensive validation and trust-building before fully integrating AI-generated predictions into high-stakes decisions for programs worth hundreds of millions. The challenge lies in proving consistent predictive accuracy across diverse and complex biological systems, moving beyond simulation as a tool to simulation as a trusted decision layer.